BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2011

View Archived Issues

SPINK1 identified as potential therapeutic target in prostate cancer

Read More

GSK-3 inhibitor SC-001 may have potential for the treatment of Parkinson's disease

Read More

Neuroprotective efficacy hypothesized for Klotho enhancers

Read More

New dual DPP IV/AP-N inhibitors prepared by IMTM

Read More

Research Development Foundation patents novel urocortin-2 analogues

Read More

New B-raf inhibitors reported by Array BioPharma and Genentech

Read More

Lilly and Avid receive FDA complete response letter for Amyvid

Read More

Vardenafil plus tamsulosin improves LUTS in subjects with BPH in long-term study

Read More

CHMP recommends approval of Lucentis in new indication

Read More

Nerviano enters into oncology license agreement with Novartis

Read More

CHMP adopts negative opinion for Vectibix in combination with chemotherapy

Read More

Insys Therapeutics reports phase III data for fentanyl sublingual spray

Read More

Lonza and Athera sign development and manufacturing agreement for PC-mAb

Read More

Scientists at Anacor Pharmaceuticals prepare new antiprotozoal agents

Read More

Regeneron and sanofi-aventis begin phase II trial of MAb SAR-231893 in eosinophilic asthma

Read More

University of Pennsylvania designs novel adamantane analogues for influenza and related disorders

Read More

Euthymics Bioscience begins EB-1010 trial for major depression

Read More

KAI Pharmaceuticals begins enrollment of phase II study of KAI-4169 in secondary hyperparathyroidism

Read More

Polaris begins enrollment in phase II trial of ADI-PEG 20 in malignant mesothelioma

Read More

KineMed extends collaboration with Bristol-Myers Squibb for Alzheimer's disease

Read More

Genentech's pivotal trial of vismodegib in advanced basal cell carcinoma meets primary endpoint

Read More

CHMP adopts positive opinion regarding new birth control pill NOMAC/E2

Read More

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

Read More

Quark terminates phase II study of PF-04523655 early, plans phase IIb study

Read More

Cell Therapeutics opens enrollment in pivotal PIX-R trial of pixantrone

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing